Loading
Lung Cancer Treatments and Mutations / Chemokine Receptors and Signaling · Journal article
British Journal of Clinical Pharmacology · September 6, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study of 828 NSCLC patients treated with EGFR-TKIs reports that concomitant H1-antihistamine use was associated with substantially reduced risk of treatment failure and mortality. The magnitude of effect is large, but the observational design cannot establish causation and results may reflect confounding by indication or unmeasured prognostic factors.
Retrospective cohort study with linked medical and cancer registry data. Patients with advanced NSCLC undergoing EGFR-TKI therapy enrolled in the Taipei Medical University Clinical Research Database (TMUCRD) linked to the Taiwan Cancer Registry.. Intervention: Concomitant prescription of H1-antihistamines during EGFR-TKI therapy. Compared with: No concomitant H1-antihistamine prescription during EGFR-TKI therapy. n = 828. Taiwan.
Concomitant H1-antihistamines reduced treatment failure risk: aHR 0.61 (95% CI 0.53–0.71, p <.001) All-cause mortality risk reduced: aHR 0.36 (95% CI 0.30–0.44, p <.001) Mean TTF longer with H1AH use: 2.09 vs. 1.25 years
No details on H1AH types, doses, or adherence; no report of adverse events or drug interactions. All-cause mortality risk reduced: aHR 0.36 (95% CI 0.30–0.44, p <.001)
If confirmed in prospective studies, concurrent H1-antihistamine use might represent a simple, low-cost adjunctive strategy to improve outcomes in EGFR-TKI-treated NSCLC. However, the observational design and potential for confounding mean this finding should not yet change clinical practice; mechanistic studies and a randomized trial would be needed to establish causation.
Retrospective cohort study with adjusted hazard ratios showing substantial associations between H1-antihistamine use and improved TTF and mortality in NSCLC patients on EGFR-TKIs, but observational design precludes causal inference and requires prospective confirmation.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in prospective studies, concurrent H1-antihistamine use might represent a simple, low-cost adjunctive strategy to improve outcomes in EGFR-TKI-treated NSCLC. However, the observational design and potential for confounding mean this finding should not yet change clinical practice; mechanistic studies and a randomized trial would be needed to establish causation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and clinical outcomes in NSCLC patients undergoing EGFR‐TKIs therapy. Methods We conducted a retrospective cohort study using the Taipei Medical University Clinical Research Database (TMUCRD) linked to the Taiwan Cancer Registry. Patients with advanced NSCLC receiving EGFR‐TKI therapy between 1 January 2008 and 31 December 2022 were classified according to concomitant prescription of H1AHs. The primary and secondary endpoints were time to treatment failure (TTF) and all‐cause mortality, respectively. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models. Sensitivity analyses and landmark analyses were performed to evaluate the robustness of the findings. Results Among 828 eligible patients, 475 (57.37%) received concomitant H1AHs during EGFR‐TKIs therapy, whereas 353 (42.63%) did not. Concomitant prescriptions of H1AHs exhibited a significantly reduced risk of treatment failure (aHR; 0.61, 95% CI; 0.53–0.71, p <.001), corresponding to longer mean TTF (2.09 vs. 1.25 years), as well as a lower risk of all‐cause mortality (aHR; 0.36, 95% CI; 0.30–0.44, p <.001). A stronger association was observed in patients with extended durations of H1AHs exposure (≥60 or ≥90 days). Conclusions Concomitant prescriptions of H1AHs with EGFR‐TKIs therapy were associated with a significantly reduced risk of treatment failure and mortality in patients with advanced NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.